Introduction
============

The Zika virus is a mosquito-borne flavivirus with an approximately 11 kilobase ribonucleic acid (RNA) genome.[@R1] The virus usually causes a mild infection in adults, symptoms include fever, arthralgia and rash.[@R2]^,^[@R3] However, severe complications can occur, such as Guillain-Barré syndrome,[@R4] meningoencephalitis,[@R5] hearing loss and uveitis.[@R6]^,^[@R7] In the current Zika virus outbreak, intrauterine infections have been associated with fetal malformations.[@R8]^--^[@R11]

Reliable detection of the Zika virus in infected people is key to understanding the epidemiology, the pathogenesis and alternative transmission routes of the virus, such as sexual intercourse and blood transfusions.[@R12] However, in areas where the Zika virus is co-circulating with dengue and chikungunya viruses, physicians cannot reliably diagnose the Zika virus infection by clinical presentation, because the viruses cause similar symptoms. Using serology for Zika virus diagnostics can be challenging because of the cross-reactivity of antibodies elicited by other endemic flaviviruses -- such as dengue, yellow fever, St Louis encephalitis and West Nile viruses.[@R3]^,^[@R13]^,^[@R14] Molecular detection of viral nucleic acid using real-time reverse transcription (RT)-polymerase chain reaction (PCR) assay is a highly reliable diagnostic method during acute infection. Currently, there are six widely used real-time RT--PCR assays for Zika virus detection.[@R7]^,^[@R13]^,^[@R15]^,^[@R16] The Pan American Health Organization (PAHO) has recommended an additional real-time RT--PCR assay.[@R12]

High real-time RT--PCR sensitivity is important to avoid false-negative results. Nucleotide mutations in the binding sites of primers and probes can affect the sensitivity.[@R17] So far, the genetic variability of the Zika virus Asian lineage causing the current American outbreak is limited to about 2% nucleotide differences across the viral genome ([Fig. 1](#F1){ref-type="fig"}). However, mutations do not occur evenly across viral genomes. Up to 10 nucleotide mismatches between the oligonucleotide sequences of the published assays and the Asian lineage consensus sequence already exist and in individual primers or probes, there are up to five mismatches ([Fig. 2](#F2){ref-type="fig"}). Note that these are worst-case scenarios based on the genetic variability permitted within the Asian Zika virus lineage, with no single known Zika virus strain accumulating all of these mismatches. However, the increasing number of divergent Zika virus outbreak strains highlights the genetic variability as a potential limiting factor of the sensitivity of Zika virus real-time RT--PCR-based diagnostics.
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Here, we compare the sensitivity of published real-time RT--PCR assays and two new assays, which we designed to have less nucleotide mismatches with the current outbreak strains. We also present data on viral load profiles in blood and urine from infected patients, using one of the new assays.

Methods
=======

Assays
------

We compared nine different assays. We included all Zika virus real-time RT--PCR assays published until 1 April 2016. These assays target the membrane (M), envelope (E), nonstructural protein (NS) 1, NS2b, NS3 and NS5 genomic domains.[@R7]^,^[@R12]^,^[@R13]^,^[@R15]^,^[@R16] We designed two new assays covering the currently known Zika virus genetic variability in the E and NS1 genomic domains ([Table 1](#T1){ref-type="table"}). These novel assays showed up to four potential mismatches per assay ([Fig. 2](#F2){ref-type="fig"}) and were designed to avoid mismatches in the most critical 3′-terminal regions of oligonucleotides that affect primer binding the most.[@R17]^,^[@R19] The new NS1 assay was additionally designed to allow cross-detection of the Spondweni virus -- the closest relative of the Zika virus -- because regions conserved between related virus taxa are expected to have less variation than other genomic regions.

###### Oligonucleotides used in Zika virus real-time reverse transcription polymerase chain reaction assays and potential nucleotide mismatches with Zika virus strains

  Assay, reference              Target genomic domain (bases)^a^   No. potential nucleotide mismatches^a^   Forward primer sequence (5' to 3')   Probe sequence (5' to 3')^b^   Reverse primer sequence (5' to 3')   Control (covered genomic region, bases)^a^   
  ----------------------------- ---------------------------------- ---------------------------------------- ------------------------------------ ------------------------------ ------------------------------------ -------------------------------------------- ------------------------------
  Lanciotti M[@R13]             M/E (939--1015)                    19                                       7                                    TTGGTCATGATACTGCTGATTGC        CGGCATACAGCATCAGGTGCATAGGAG          CCTTCCACAAAGTCCCTATTGC                       uncRNA; IVT I (811--1500)
  Lanciotti E[@R13]             E (1190--1266)                     18                                       4                                    CCGCTGCCCAACACAAG              AGCCTACCTTGACAAGCAGTCAGACACTCAA      CCACTAACGTTCTTTTGCAGACAT                     uncRNA; IVT I (811--1500)
  Bonn E (this study)           E (1188--1316)                     0                                        0                                    AGYCGYTGYCCAACACAAG            CCTMCCTYGAYAAGCARTCAGACACYCAA        CACCARRCTCCCYTTGCCA                          uncRNA; IVT I (811--1500)
  Pyke E[@R16]                  E (1326--1397)                     28                                       7                                    AAGTTTGCATGCTCCAAGAAAAT        ACCGGGAAGAGCATCCAGCCAGA              CAGCATTATCCGGTACTCCAGAT                      uncRNA; IVT I (811--1500)
  Pyke NS1[@R16]                NS1 (3433--3498)                   13                                       7                                    GCACAATGCCCCCACTGT             TTCCGGGCTAAAGATGGCTGTTGGT            TGGGCCTTATCTCCATTCCA                         uncRNA; IVT II (3 145--3739)
  Bonn NS1 (this study)         NS1 (3385--3495)                   4                                        3                                    CRACYACTGCAAGYGGAAGG           ATGGTGCTGYAGRGARTGCACAATGC           GCCTTATCTCCATTCCATACC                        uncRNA; IVT II (3145--3739)
  PAHO NS2b[@R12]               NS2b/NS3 (4538--4628)              11                                       4                                    CTGTGGCATGAACCCAATAG           CCACGCTCCAGCTGCAAAGG                 ATCCCATAGAGCACCACTCC                         uncRNA; IVT III (4246--4882)
  Tappe NS3[@R7]                NS3 (6012--6106)                   15                                       10                                   TGGAGATGAGTACATGTATG           CTGATGAAGGCCATGCACACTG               GGTAGATGTTGTCAAGAAG                          uncRNA; IVT IV ( 770--6370)
  Faye NS5[@R15]                NS5 (9376--9477)                   6                                        3                                    AARTACACATACCARAACAAAGTGGT     CTYAGACCA**[GCTG]{.ul}**AAR^c^       TCCRCTCCCYCTYTGGTCTTG                        uncRNA; IVT V (9100--9696)
  Marker assay 1 (this study)   M/NS1                              N/A                                      N/A                                  GCATCCAGCCAGAGAATCTG           TGCTGTCAGTTCACTCAAGGTTAGAGA          CAATAACGGCTGGATCACACTC                       uncRNA (N/A)
  Marker assay 2 (this study)   NS3/NS4b-NS5                       N/A                                      N/A                                  CTTGACAATATTTACCTCCAAGATG      CATAGCCTCGCTCTCTACACATGAGA           GTTGCTTTTCGCTCCAGAGAC                        uncRNA (N/A)

E: envelope; IVT: in vitro transcribed ribonucleic acid; M: membrane; N/A: not applicable; NS: nonstructural protein; PAHO: Pan American Health Organization; uncRNA: universal control ribonucleic acid.

^a^ Nucleotide position according to GenBank® accession number: KU321639.

^b^ All probes are labelled with fluorescein amidite (FAM) at the 5′-end and a Black Hole Quencher® at the 3′-end.

^c^ Locked nucleic acid bases are underlined.

Controls
--------

All controls are based on a current Zika virus outbreak strain (GenBank® accession number KU321639). As positive controls, we generated five assay-specific quantified in vitro transcripts (IVT) for the respective genomic target regions. Data on analytical sensitivity, including the standardized measure lower limit of detection, are not available for most of the published assays. To enable stoichiometrically exact analyses of the lower limit of detection for all of the assays, we joined all target domains into a quantative universal control ribonucleic acid (uncRNA) containing all of the assays' target regions on one RNA strand ([Fig. 3](#F3){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). All controls can be acquired via the European Virus Archive at the following links: Zika virus IVT I available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1598&id_rubrique=9>; Zika virus IVT II available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1599&id_rubrique=9>; Zika virus IVT III available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1600&id_rubrique=9>; Zika virus IVT IV available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1601&id_rubrique=9>; Zika virus IVT V available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1602&id_rubrique=9>; and uncRNA 1.0 available at: <http://www.european-virus-archive.com/Portal/produit.php?ref=1603&id_rubrique=9>.
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The uncRNA was generated as described previously.[@R20] In brief, the uncRNA was custom designed as a gBlocks® fragment with a T7 promotor sequence (Integrated DNA Technologies, Leuven, Belgium) and in vitro transcribed.[@R20]

A disadvantage of using a test control with a high concentration of viral RNA (e.g. from cell culture) is the potential for laboratory contamination, potentially causing false-positive test results. In contrast to natural viral RNA, potential cases of laboratory contamination with the uncRNA can be proven by two real-time RT--PCR marker assays we designed specifically to detect the uncRNA ([Table 1](#T1){ref-type="table"}). These two marker assays contain detection probes that target the overlap of two joined genomic target domains, which do not naturally occur in the Zika virus genome ([Fig. 3](#F3){ref-type="fig"}).

Quantification and characterization
-----------------------------------

We purified viral RNA using the Qiagen Viral RNA Mini Kit (Qian, Hilden, Germany) or the MagNA Pure 96 Viral NA Small Volume Kit (Roche, Basel, Switzerland) according to the manufacturer\'s instructions. Dengue virus RNA quantification and flavivirus typing were done as described previously.[@R21]^,^[@R22]

For all of the experiments, except when assessing threshold cycle variation using different reaction conditions and thermocyclers, we quantified Zika virus RNA using the LightCycler® 480 Instrument II (Roche, Basel, Switzerland). Generally, 25 μl reactions were set up with 5 μl of RNA; 12.5 μl of 2 × reaction buffer from the Superscript® III one step RT--PCR system with Platinum® Taq polymerase (Thermo Fisher Scientific, Darmstadt, Germany); 0.4 μl of a 50 mM magnesium sulfate solution (Thermo Fisher Scientific); 1 μg of nonacetylated bovine serum albumin (Roche), 600 nM of each primer and 280 nM of each probe and 1 μl of SuperScript® III RT/Platinum® Taq mix. Amplification involved 50 °C for 15 minutes, followed by 95 °C for 3 minutes and 45 cycles of 95 °C for 15 seconds, 56 °C for 20 seconds and 72 °C for 15 seconds. For comparison of C~T~ values using different PCR cyclers and chemistry, we used the Bonn E- and NS1-based assays using either the Superscript III One-Step RT--PCR kit (Thermo Fischer) or the Qiagen® One-Step RT--PCR kit (Qiagen) on a Roche LightCycler® 480 and LightCycler 2.0, a Qiagen Rotor Gene HQ and an Applied Biosystems 7500 thermocycler. Reference conditions refer to the usage of Life Technologies SuperScript® III One-Step enzyme mix and a Roche LightCycler® 480 thermocycler as described above.

Probit regression analyses, to determine the lower limit of detection for all real-time RT--PCR assays, were done using SPSS V22 (IBM, Ehningen, Germany) and eight parallel test replicates.

Clinical specimens
------------------

We obtained clinical specimens from travellers for which routine medical investigation of either Zika or dengue virus had been requested due to compatible clinical symptoms or a travel history to affected countries. The travellers had acquired their infections in Brazil, the Dominican Republic or Suriname during 2015 and 2016.

We spiked a Zika virus-negative human plasma and urine sample with defined quantities of the African Zika virus strain MR766 and an Asian lineage outbreak strain H/PF/2013. Spiked samples were serially diluted and two replicates of each dilution were individually purified using the MagNA Pure 96 Viral NA Small Volume Kit with an input volume of 200 μL and an extraction volume of 100 μL.

Results
=======

All assay-specific IVT and the uncRNA allowed comparable quantification of Zika virus RNA with a mean twofold deviation of results (maximum deviation: sixfold), suggesting the ability to use these controls to generate comparable results even when different real-time RT--PCR assays are used in different laboratories. The two marker assays showed no detection of Zika virus RNA even upon using RNA from high-titred cell culture isolates (10^6^--10^9^ RNA copies/mL) as a real-time RT--PCR template.

To ensure specific detection of the Zika virus, we evaluated all assays using 37 high-titred cell culture isolates of different flaviviruses or chikungunya virus (the list of tested isolates is available from the corresponding author). None of the published assays detected the co-circulating alphavirus chikungunya virus or any other flavivirus. As expected, an Asian Zika virus lineage-specific E-based assay[@R16] did not detect the African lineage despite very high concentrations of viral RNA in the sample. As intended, the new NS1-based assay cross-detected Spondweni virus, as well as Kokobera and Jugra virus. These viruses are predominantly animal-associated[@R23] and do not circulate in Latin America and hence do not affect people in the current Zika virus outbreak.[@R14]

When we determined the lower limit of detection using the uncRNA, all but two assays showed comparably high analytical sensitivities of around 5--10 Zika virus RNA copies/reaction ([Fig. 4](#F4){ref-type="fig"}). An NS2b-based assay recommended by PAHO showed a lower limit of detection of 17 copies/reaction,[@R12] whereas an NS3-based assay showed a lower limit of detection of 1373 copies/reaction.[@R7] To exemplify the impact of technical sensitivity on clinical sensitivity, we extrapolated the lower limits of detection to clinical viral loads. As shown in [Table 2](#T2){ref-type="table"}, an assay with a lower limit of detection of 5--10 copies/reaction has a clinical detection limit of about 1000 copies/mL, whereas an assay with a lower limit of detection of 1000 copies/reaction has a clinical detection limit of about 10000 copies/mL. To improve clinical sensitivity, RNA purification methods could be optimized by using larger input volumes of the clinical samples ([Table 2](#T2){ref-type="table"}).
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###### Analytical sensitivity of Zika virus real-time reverse transcription polymerase chain reaction assays

  Assay, reference        Technical 95% lower limit of detection, copies per reaction (95% CI)   Extrapolation of LOD to clinical viral loads, copies/mL   
  ----------------------- ---------------------------------------------------------------------- --------------------------------------------------------- ---------
  Lanciotti M[@R13]       3.2 (2.2--8.3)                                                         640                                                       320
  Lanciotti E[@R13]       4.1 (2.7--11.4)                                                        820                                                       410
  Bonn E (this study)     2.1 (1.4--8.0)                                                         420                                                       210
  Pyke E[@R16]            5.3 (3.0--25.7)                                                        1 100                                                     530
  Pyke NS1[@R16]          12.1 (5.9--78.5)                                                       2 400                                                     1 210
  Bonn NS1 (this study)   3.1 (2.3--5.8)                                                         620                                                       310
  PAHO NS2b[@R12]         17.0 (12.3--30.9)                                                      3 400                                                     1 700
  Tappe NS3[@R7]          1 377.3 (860.3--5 162.4)                                               280 000                                                   138 000
  Faye NS5[@R15]          8.0 (4.5--43.9)                                                        1 600                                                     800

CI: confidence interval; E: envelope; LOD: lower limit of detection; M: membrane; RNA; ribonucleic acid; NS: nonstructural protein.

^a^ Using 5 μL of eluted ribonucleic acid per polymerase chain reaction.

^b^ Corresponding to twice higher input (e.g. 140 μl) than elution volumes (e.g. 70 μl), such as those in the commonly used Qiagen Viral RNA Mini Kit (Qiagen, Hilden, Germany), assuming a 100% extraction efficacy.

We examined the assays' sensitivity in different clinical specimens by incorporating the step of RNA purification and using Zika virus-negative human blood and urine samples spiked with 10^2^--10^6^ copies/mL of either Zika virus representing the Asian lineage (strain H/PF/2013) or the African lineage (strain MR766). The results were consistent with lower limit of detections for the uncRNA. The assays with high analytical sensitivities could detect 10^3^ Zika virus RNA copies/mL of blood or urine in at least one replicate experiment, whereas the assay with the lowest analytical sensitivity yielded negative results even at high Zika virus concentrations of 10^5^ and 10^6^ copies/mL ([Fig. 5](#F5){ref-type="fig"}).
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We explored the variability of the threshold cycle (C~T~) values -- which could vary due to PCR instruments and reagents used -- by testing our two new assays under diverse reaction conditions including reagents by different suppliers and different real-time RT--PCR instruments. Even a variation of only two variables could yield up to 4.3 cycles in difference in the C~T~ values for the same virus target concentration, which corresponds to about 20-fold deviations in viral load results ([Fig. 6](#F6){ref-type="fig"}). Therefore, using C~T~ values for comparison of viral loads between studies might be misleading.[@R24]^,^[@R25]
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According to preliminary studies, short-term viremia and low viral loads complicate Zika virus detection in blood.[@R13]^,^[@R26] Since Zika virus RNA has been detected in urine from Zika virus-infected patients for two weeks or longer,[@R26] we investigated whether blood or urine were the most suitable clinical specimens for diagnoses of acute Zika virus infection. We used the new NS1-based assay to quantify viral loads in 21 serum samples and 12 urine samples from 24 patients infected with virus strains from the current outbreak. As shown in [Fig. 7](#F7){ref-type="fig"}, viral loads generally decreased during 2 to 12 days after symptom onset. Matched urine and blood samples taken on the same day were available from six patients. One patient had a lower viral load in urine, than in blood, two patients had an equal viral load in both samples and three patients had a higher viral load in urine than in blood ([Fig. 8](#F8){ref-type="fig"}). Mean viral loads in all the available clinical samples (including those without known date of symptom onset) were 5x10^4^ RNA copies/mL of blood (range: 1x10^2^--2x10^6^) and 2x10^4^ RNA copies/mL of urine (range: 4x10^2^--8x10^4^). The viral loads in the 24 specimens sampled in the first 12 days after symptom onset were comparable to viral loads in serum from patients sampled during the Zika virus outbreak in the Federated States of Micronesia[@R13] in 2007 ([Fig. 9](#F9){ref-type="fig"}). A combined data set of 41 samples comprising the data from the 2007 outbreak (17 samples)[@R13] and this study (24 samples) resulted in mean viral loads of 1 × 10^4^ RNA copies/mL of blood (range: 1 × 10^2^--4 × 10^5^) and 5 × 10^3^ RNA copies/mL of urine (range: 4 × 10^2^--6 × 10^4^). The samples were taken during comparable intervals: within 11 days after symptom onset for urine and within 12 days after symptom onset for serum samples. Two of these 41 samples contained viral loads of less than 5 × 10^2^ RNA copies/mL ([Fig. 9](#F9){ref-type="fig"}), leading to an estimated risk of false-negative test results of 5% even when using highly sensitive assays with a technical lower limit of detection of 5 copies/reaction (equivalent to 5 × 10^2^ copies/mL; [Fig. 10](#F10){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Using an insensitive assay with a lower limit of detection of 1 × 10^4^ copies/reaction, the proportion of estimated false-negative test results is about 50% ([Fig. 10](#F10){ref-type="fig"}).
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Many of the laboratories in countries affected by the current outbreak that are conducting Zika virus testing also have experience in detecting and quantifying dengue virus. To compare the risk of false-negative test results between these two viruses, we quantified 38 clinical samples positive for dengue virus,[@R21] that had been sent to our laboratories for medical diagnostics previously. The mean viral load of dengue was 5 × 10^5^ RNA copies/mL (range: 5 × 10^2^--5 × 10^8^; [Fig. 11](#F11){ref-type="fig"}), meaning that viral loads of dengue in blood were generally about 100-fold higher than viral loads of Zika virus (*t*-test, *P* = 0.03). Accordingly, the estimated risk of false-negative results was several-fold lower for dengue than for the Zika virus ([Fig. 10](#F10){ref-type="fig"} and [Fig. 12](#F12){ref-type="fig"}).
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Discussion
==========

This study provides guidance on the choice of method for diagnosing Zika virus infections and a molecular control that enables the comparison of results between different laboratories and studies. The low viral loads presented in this and a previous study[@R13] suggest a possibility of false-negative test results when using real-time RT--PCR assays in diagnostics.

The results presented here suggest that some published real-time RT--PCR assays may be of limited use for clinical diagnostics during the current Zika virus outbreak. One NS3-based assay that was intended for virus typing should not be used for diagnostics because of its low sensitivity.[@R7] Some other assays have features that potentially limit their use in the current outbreak, including limited access to specific probe formats (e.g. the Faye NS5-based assay),[@R15] relatively lower analytical sensitivity and high numbers of potential mismatches with members of the Asian Zika virus lineage.[@R7]^,^[@R14] Our novel assays may be more robust against genetic variation, but real-time monitoring of all assays' oligonucleotide binding regions is required during the current situation. According to our data, the Lanciotti E-,[@R13] the Pyke E- and NS1-,[@R16] the Bonn E- and the Bonn NS1-based assays are highly sensitive for the Asian Zika virus lineage and show few mismatches within genomic domains targeted by these assays. With the present knowledge of Zika virus variability, we suggest that laboratories can use these five assays for diagnostics during the current outbreak and preferably combine at least two assays to increase clinical sensitivity.[@R13]

The low viral loads we detected in urine and blood samples are in agreement with two previous studies reporting quantitative data.[@R13]^,^[@R26] In contrast to data from six patients from French Polynesia,[@R26] we did not observe a significant difference in the viral loads between the urine and blood samples. Hence, our data do not support urine as a generally more suitable clinical specimen to detect the Zika virus. However, since Zika virus RNA seems to remain detectable in urine and semen longer than in blood,[@R26]^--^[@R29] we suggest that both blood and urine samples should be used for reliable Zika virus diagnostics. The Zika virus has also been detected in saliva,[@R28]^,^[@R30] but we could not evaluate the suitability of saliva samples because we did not have access to such samples.

Although commercial diagnostic real-time RT--PCR reagents for Zika virus detection are available, laboratories in areas affected by the Zika virus outbreak often use non-commercial formulations because of resource constraints.[@R12]^,^[@R20] The non-commercial assays are difficult to standardize and compare. The transfer of essential reagents with coordinated implementation of laboratory protocols and practical training for staff can strengthen accurate real-time RT--PCR diagnostics in resource-constrained settings.[@R20]^,^[@R31]^--^[@R33] Among the most essential contributions to technology transfer is the provision of standardized control material that can be shipped internationally without biosafety concerns. Research consortia and public health structures can use these reagents to establish a technical basis for test implementation, as demonstrated for severe acute respiratory syndrome and Middle East respiratory syndrome-coronaviruses.[@R34]^,^[@R35] When these viruses emerged, they were novel and new diagnostic tests had to be developed along with the provision of reagents to laboratories. However, for the detection of the Zika virus, where test formulations are already available, assay standardization can only work with the provision of a reference reagent that is universally applicable in all assays, such as our uncRNA reagent or a multicentre validated natural virus standard. Quantitative comparability between studies will enable relative estimates of the transmission risks associated with blood transfusion and solid organ transplantations as well as the transmission risks from body fluids such as semen or saliva. Quantitative data may also shed light on Zika virus pathogenesis, since a higher viral load may be associated with more severe clinical complications, as shown in other arboviral infections, such as those caused by dengue, chikungunya and Crimean-Congo haemorrhagic fever viruses.[@R36]^--^[@R38]

Low viral loads in patients imply a high risk of false-negative test results. Until 7 April 2016, only 3% of 199 922 suspected Zika virus cases could be laboratory-confirmed in the PAHO Region.[@R39] The low number of confirmed cases could be due to the difficulty in processing high numbers of diagnostic requests in resource-constrained settings. A study from Puerto Rico, showed that 30 (19%) of 155 patients with suspected Zika virus disease could be laboratory-confirmed using molecular and serologic tools.[@R40] In addition, a study from Brazil demonstrated that 119 (45%) of 262 patients with suspected Zika virus infection had a positive real-time RT--PCR result.[@R41] The higher proportion of laboratory-confirmed cases in those studies and our data suggest that a considerable proportion of patients with low viral loads may have gone undiagnosed by molecular testing during the current outbreak.

Endemic countries also need highly sensitive molecular Zika virus detection methods to ensure safe blood transfusions. The Zika virus has been detected in 3% of blood donors in previous outbreaks[@R42] and transfusion-associated transmission has been reported in Brazil.[@R43] Our comparison of blood viral loads and real-time RT--PCR sensitivity suggest a risk of false-negative results during pooled and even individual blood donor screening. Such risk has been reported for the West Nile virus, where several people have acquired the virus through blood transfusion or solid organ transplantation, because of false-negative real-time RT--PCR results.[@R44]

The association of Zika virus infection and fetal malformations demand reliable Zika virus diagnostics for pregnant women.[@R8]^--^[@R11] The current sensitivity of real-time RT--PCR assays suggests that molecular testing during pregnancy may preferentially diagnose highly viremic pregnant women. If intrauterine Zika virus infections and the congenital malformations correlate positively with high Zika virus concentrations, the limited test sensitivity might influence estimates of the manifestation index of congenital disease. The low viral loads in many patients suggest a limited capacity for molecular protocols to exclude Zika virus infection in highly affected areas. Hence, cohort studies investigating Zika virus pathogenesis in pregnant women need to do additional serological testing.

In conclusion, our data emphasize the need for highly sensitive assays in molecular Zika virus diagnostics. In addition to an appropriate choice of method, clinical sensitivity can be increased by testing several specimens per patient, by using more than one real-time RT--PCR target, optimizing RNA purification from clinical samples and by combining molecular and serological testing.[@R13] The uncRNA reagent -- used as a universal quantitative positive control -- can ensure high sensitivity and good comparability of qualitative and quantitative results in diagnostic laboratories and clinical studies.
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